Company news
Alto Neuroscience, Inc. (NYSE:ANRO) news
Alto Neuroscience, Inc. news releases on 6ix. Latest, Aug 27, 2026: Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Press releases & updates
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
August 27, 2026
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
July 13, 2026
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
June 15, 2026
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
May 28, 2026
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
May 15, 2026
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
May 4, 2026
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
April 21, 2026
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
April 1, 2026
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
March 23, 2026
Alto Neuroscience Announces $120 Million Private Placement Financing
March 16, 2026
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
March 16, 2026
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
March 13, 2026
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
February 23, 2026
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
February 13, 2026
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
February 3, 2026
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
January 14, 2026
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
January 13, 2026
Alto Neuroscience : Corporate Presentation
January 12, 2026
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
December 3, 2025
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 12, 2025
Alto Neuroscience to Participate in Upcoming Investor Conferences
October 28, 2025
Alto Neuroscience Announces $50 Million Private Placement Financing
October 20, 2025
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
October 20, 2025
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
October 3, 2025
Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
September 9, 2025
Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 13, 2025
Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
August 13, 2025
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
June 30, 2025
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
June 26, 2025
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
June 3, 2025
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
May 29, 2025
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 14, 2025
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach
April 28, 2025
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
April 22, 2025
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
March 20, 2025
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
February 19, 2025